Merck er en blue-chip-aksje som tilbyr defensiv helseeksponering med konsistent inntjening, en sterk balanse og en bevist evne til å innovere gjennom FoU og strategiske oppkjøp.
Merck er en farmasøytisk gigant forankret av Keytruda, verdens best-selgende onkologi-medisin, som kombinerer en robust pipeline med tiår med pålitelige utbyttebetalinger.
Merck er en farmasøytisk megakapsje drevet av Keytruda, den best-selgende kreftimmunterapien globalt, med en diversifisert pipeline innen onkologi, vaksiner og dyrehelse.
Merck er en av verdens viktigste farmasøytiske aksjer, forankret av Keytruda—den best-selgende kreftmedisinen globalt—med en dyp pipeline innen onkologi, vaksiner og kardiometabolsk sykdom.
Data updated Feb 15 · Source: Twelve Data
Merck has delivered exceptional performance, trading near its 52-week high of $123.33 with a remarkable 59% gain over six months and 42% over the past year. The stock's momentum is strong, sitting well above its 50-day moving average of $108. At a P/E of 14.88 with EPS of $8.16, Merck offers compelling value relative to pharma peers.
The bull case centers on Keytruda, the world's top-selling drug, along with a diversified pipeline spanning oncology, vaccines, and animal health. Merck's acquisition strategy (notably Prometheus Biosciences and recent deals) strengthens its post-Keytruda outlook. Financial health remains robust with consistent free cash flow generation.
The bear case involves Keytruda's patent cliff around 2028, which represents roughly 50% of pharmaceutical revenue. Pipeline execution risk and pricing pressures from potential Medicare negotiations add uncertainty. While Merck has raised its dividend for over a decade, the yield remains modest compared to true dividend aristocrats.
Overall, Merck represents a well-managed pharmaceutical giant with near-term strength but meaningful long-term transition risk that investors should monitor closely.
Merck stands as a formidable player in the global healthcare landscape, anchored by its dominant oncology franchise, particularly Keytruda, and a resilient animal health business. Trading near its 52-week high of $122.66, the stock has shown significant momentum, currently sitting well above its 50-day moving average. A P/E ratio of 25.07 suggests a premium valuation compared to some industry peers, reflecting high market expectations for its pipeline execution and recent earnings growth. While the company boasts strong cash flows and solid fundamentals, the primary risk remains its heavy revenue concentration in Keytruda and the looming patent cliff later this decade. Investors must weigh this concentration risk against Merck's aggressive M&A strategy and pipeline diversification. Overall, Merck represents a high-quality defensive holding, though the current valuation demands successful clinical outcomes to justify further upside.
Latest from Otrai
A stock index is a single number that summarizes the price action of a basket of companies. The S&P 500 tracks roughly 500 large US firms, the Nasdaq-100 tracks the 100 largest non-financial names on the Nasdaq exchange, and the Dow Jones Industrial Average follows 30 blue-chip stocks.
The Greeks explain why an option costs what it costs and how that price changes when the stock moves, time passes, and volatility shifts. Delta, Gamma, Theta, and Vega, made accessible.
Chart patterns are the most recognizable part of technical analysis and the most misunderstood. Most fail or break out the wrong way before reversing. This guide covers head and shoulders, double tops and bottoms, triangles, and flags — with realistic reliability, target measurement, and false-breakout confirmation.
Hver trader har en strategi som ser flott ut i hodet deres. Backtesting er hvordan du finner ut om den faktisk fungerer. Her er hvordan du tester strategier på riktig måte, hvilke beregninger som betyr noe, og hvorfor de fleste backtestresultater er for gode til å være sant.
Powered by Rexiew